However, in vitro FXR-activated human monocytes from pwMS and healthy controls show an increased IL-10 secretion, highlighting the potential therapeutic effect of FXR agonists as an MS treatment [65]. The gene discussed is NR1H4; the disease is myeloid sarcoma.